Chairman of the Positron Corporation (OTCBB: POSC) Confirms Talks; Sources Say Partnership or Buy-Out News May Follow

LOS ANGELES, CA, Apr 22 (MARKET WIRE) --
As rumors of a lucrative buy-out or partnership continue to swirl,
Patrick G. Rooney, the Chairman of the Board of Positron Corporation
(OTCBB: POSC) -- a molecular imaging company focused on Nuclear
Cardiology -- has confirmed in an interview with BioMedReports that his
company "is currently in discussions with a potential partner in our
industry."

While Rooney did not offer any assurances or details about when an
agreement might be reached. Over the past two weeks, however, multiple
sources have told the news portal which covers Wall Street's biomedical
sector and delivers financial and investment intelligence to a community
of highly informed investors that details about "a big announcement
involving Positron and a much larger publicly traded NYSE company" could
come as early as next Monday.

BioMedReports told its subscribers on Wednesday that stock prices for the
twenty-seven-year-old company could see substantial gains now that the
company had positioned itself to be the leader in nuclear cardiology
imaging. Positron's PET scanner, known as the "Attrius," has robust
cardiac specific imaging software and, more importantly, is the only
"PET" imaging device in the industry.

In a letter to shareholders last month, Rooney informed investors that
"Positron has several immediate opportunities with some of the largest
companies in the nuclear medicine industry. Any combination of success
with these opportunities will have a tremendous positive present and
future impact on Positron."

According to today's exclusive report, Rooney feels confident that his
company will thrive financially given that "the cardiac business is five
times greater than the oncology business."

"Everyone has a heart problem; not everyone has cancer," said Rooney.
"Once you have a heart issue, they'll put you on some kind of imaging
device to test your heart. It's just where medicine is going. Everyone
over 45 or so is starting to get imaged at the first sign of any heart
issues."

Positron recently won the 2010 Frost and Sullivan "North American
Molecular Imaging Systems New Product Innovation Award."

The complete special report and video about the company is available at
BioMedReports.Com.

Biotech investors interested in accessing the news portal's database of
clinical trials and upcoming FDA decisions can access that information
here:

http://biomedreports.com/fda-calendar/fda-calendar.html

About BioMedReports.Com

BioMedReports.Com is a news portal covering the biomedical news and
financial sector. BioMedReports is not paid or compensated to report news
and developments about publicly traded companies.

For more biomedical sector and investment news go to
http://BioMedReports.com

Media Contact:
Mary Davila, Assistant Editor, BioMedReports.Com
e-mail: info@biomedreports.com Tel: +1 323 472 4480 Fax: +1 888 210 3556

Copyright 2010, Market Wire, All rights reserved.

-0-